Wanbang Pharmaceutical's stock trading fluctuation and risk warning announcements. The company recently paid attention to media and stock community reports that the relevant information relating to Wanbang Pharmaceutical's promotion of innovative taxicillin A controlled-release tablets in the core pipeline and signing cooperation agreements for new drugs such as fever is false; the company's 2026 semi-annual results have not been disclosed to the outside world, and no performance forecast has yet been released.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.